ReviewGeroScience2019
Lipotoxicity, aging, and muscle contractility: does fiber type matter?
Review in GeroScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 61 citations in OpenAlex.
- Impact of obesity and type 2 diabetes on muscle power, quality, and force-velocity, and their relation to functional capacity.Journal of diabetes and metabolic disorders · 2026Article
- Association between TMG-derived contractile muscle parameters and MRI-based muscle structure in sarcopenia.BMC musculoskeletal disorders · 2026Article
- Effects of bed rest and immobilization on intramuscular and intermuscular adipose tissue: A systematic review.Experimental physiology · 2026Review
- Transcriptomic analysis demonstrates moderators of muscle quality are altered in age-related sarcopenic obesity.BMC genomics · 2025Article
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- Association between cognitive impairment and comprehensive weight phenotypes among older adults in China: a nationwide survey.Aging clinical and experimental research · 2025Article
- Targeting intramyocellular lipids to improve aging muscle function.Lipids in health and disease · 2025Review
- Metabolomic Pathways of Inflammation and Mitochondrial Dysfunction Are Related to Worsening Healthy Aging Index and Mortality.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025Review
- Review
- Article
- How soon do metabolic alterations and oxidative distress precede the reduction of muscle mass and strength in Wistar rats in aging process?Biogerontology · 2024Article
- Fatty infiltration in the musculoskeletal system: pathological mechanisms and clinical implications.Frontiers in endocrinology · 2024Review
- Mechanisms of Extraorbital Lacrimal Gland Aging in Mice: An Integrative Analysis of the Temporal Transcriptome.Investigative ophthalmology & visual science · 2023Article
- Physiological Approaches Targeting Cellular and Mitochondrial Pathways Underlying Adipose Organ Senescence.International journal of molecular sciences · 2023Review
- An Integrated Approach to Skeletal Muscle Health in Aging.Nutrients · 2023Review
- Palmitic Acid Inhibits Myogenic Activity and Expression of Myosin Heavy Chain MHC IIb in Muscle Cells through Phosphorylation-Dependent MyoD Inactivation.International journal of molecular sciences · 2023Article
- Sarcopenia: Molecular regulatory network for loss of muscle mass and function.Frontiers in nutrition · 2023Review
- Lipotoxicity-related sarcopenia: a review.Journal of medicine and life · 2022Review
- New Horizons in the Treatment of Age-Associated Obesity, Sarcopenia and Osteoporosis.Drugs & aging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Sarcopenia is a universal characteristic of the aging process and is often accompanied by increases in whole-body adiposity. These changes in body composition have important clinical implications, given that loss of muscle and gain of fat mass are both significantly and independently associated with declining physical performance as well as an increased risk for disability, hospitalizations, and mortality in older individuals. This increased fat mass is not exclusively stored in adipose depots but may become deposited in non-adipose tissues, such as skeletal muscle, when the oxidative capacity of the adipose tissue itself is exceeded. The redistributed adipose tissue is thought to exert detrimental local effects on the muscle environment given the close proximity. Thus, sarcopenia observed with aging may be better defined in the context of loss of muscle quality rather than loss of muscle quantity per se. In this perspective, we briefly review the age-related physiological changes in cellularity, secretory profiles, and inflammatory status of adipose tissue which drive lipotoxicity (spillover) of skeletal muscle and then provide evidence of how this may affect specific fiber type contractility. We focus on biological contributors (cellular machinery) to contractility for which there is some evidence of vulnerability to lipid stress distinguishing between fiber types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.